Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciag270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Mary Feser und 18 weiteren Autor:innen. Beteiligte Einrichtung: Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Meningitis, Cryptococcal, Cost-Benefit Analysis, AIDS-Related Opportunistic Infections, Health Services Accessibility. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH, Massachusetts General Hospital, Bill & Melinda Gates Foundation.
Abstract (Originalsprache)
Background
Cryptococcal meningitis (CM) causes 13%–20% of deaths among people with HIV (PWH) globally. We examined the cost-effectiveness of improving access to CM diagnostics and treatment among PWH initiating HIV care with a positive serum cryptococcal antigen (CrAg) test in Malawi.
Methods
We used the CEPAC-I model to simulate (1) Current care (CM treatment if diagnosed with CM; otherwise preemptive fluconazole) and assessed 7 intervention strategies to expand care: (2) lumbar puncture (LP); (3) semi-quantitative serum CrAg (CrAgSQ) alone; or (4) CrAgSQ plus confirmatory LP for asymptomatic people with CrAg+; and (5) 98% access to liposomal amphotericin B/flucytosine/fluconazole (LAmB/5FC/Fluc) for diagnosed CM, as well as improving access to CM treatment with each diagnostic strategy (6, 7, 8). The simulated cohort has mean CD4 27/µL, age 37 years; 16% have symptomatic CM, 28% asymptomatic CM, and 56% asymptomatic cryptococcemia. Model outcomes include 1-year survival, quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs) assessed at 2 cost-effectiveness thresholds: US$150/QALY and US$600/QALY.
Results
Current care results in 70% 1-year survival, 10.67 QALYs, and costs US$2290/person. 98% access to LAmB/5FC/Fluc increases survival (+2.2%) and QALYs (+0.33 undiscounted QALYs) at lifetime costs of US$2320/person (ICER, US$140/QALY). CrAgSQ plus confirmatory LP for asymptomatic CrAg+ and 98% access to LAmB/5FC/Fluc results in +6.0% 1-year survival, +0.97 QALYs, +US$190/person (ICER, US$380/QALY). Results are sensitive to test characteristics and uptake.
Interpretation
Improving access to LAmB/5FC/Fluc and expanding diagnostics to improve detection of asymptomatic CM would improve clinical outcomes and be cost-effective in Malawi and similar settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Research Department, Elizabeth Glaser Pediatric AIDS Foundation Malawi, Lilongwe, Malawi.
- HIV Team, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
- Department of Global HIV, Hepatitis, and Sexually Transmitted Diseases, World Health Organization, Geneva, Switzerland.
- Strategic Information and Evaluation, Elizabeth Glaser Pediatric AIDS Foundation, Maputo, Mozambique.
- Botswana-Harvard Health Partnership, Gaborone, Botswana.
ORCID-Profile: Ajay Rangaraj, Virginia R Talbot, Yiqi Qian, David S Lawrence, Eltas Nyirenda-Dziwani, Andrew Phillips, Kenneth A Freedberg, Joseph N Jarvis, Emily P Hyle
Förderung
- NIH
- Massachusetts General Hospital
- Bill & Melinda Gates Foundation
- NIAID NIH HHS
- World Health Organization
- UK National Institute for Health and Care Research
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Feser, M., Maphosa, T., Shroufi, A., Rangaraj, A., Talbot, V. R., Songane, M., Qian, Y., Matiya, E., Lawrence, D. S., Arena, C., Srinivasan, A., Nyirenda-Dziwani, E., Ford, N., Nyirenda, R., Phillips, A., Freedberg, K. A., Tiam, A., Jarvis, J. N., & Hyle, E. P. (2026). Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag270
Vancouver
Feser M, Maphosa T, Shroufi A, Rangaraj A, Talbot VR, Songane M, et al. Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag270
BibTeX
@article{Feser2026,
author = {Feser, Mary and Maphosa, Thulani and Shroufi, Amir and Rangaraj, Ajay and Talbot, Virginia R and Songane, Mario and Qian, Yiqi and Matiya, Eddie and Lawrence, David S and Arena, Caroline and Srinivasan, Anjali and Nyirenda-Dziwani, Eltas and Ford, Nathan and Nyirenda, Rose and Phillips, Andrew and Freedberg, Kenneth A and Tiam, Appolinaire and Jarvis, Joseph N and Hyle, Emily P},
title = {Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag270}
}
EUVIMED